Earlier this year, Venture Capitalist Dendy Young and partner George Mason University Professor Emanuel Petricoin launched new biotech company Perthera or Personalized Cancer Therapy Inc. According to the Washington Business Journal, the firm combines high-end personalized medicine tactics and advanced analytics.
Since its launch in March, the firm has consulted with about 50 customers, each who pay $6,000 for a molecular profile of their tumor and a detailed report back to their primary physician. As revealed by the Washington Business Journal, Perthera performs a biopsy and then contracts with other biotech companies to analyze cellular proteins and the genetic profile of the tumor.
Results of the analytics and the data analysis on customers can help oncologists make better decisions on what treatments are more likely to work.
